Skip to main content

Featured

Stellantis May Abandon Brampton for Good: What It Means for Ontario Jobs

  Published August 18, 2026 With less than 24 hours left before Washington's 50% tariff deadline hits at 12:01 a.m. Wednesday, the headlines are all about cement, wine, and dairy. But the real fight holding up a deal is happening in the auto sector — and this week it collided with a story much closer to home: Stellantis is weighing whether to walk away from its Brampton, Ont. assembly plant for good. Put those two stories together and you get a clearer picture of what's actually at stake for Ontario workers, renters, and taxpayers than any tariff-deadline countdown can show on its own. The Trade Deal Is Stuck on Auto Rules, Not Wine or Cement Canadian and U.S. negotiators have been in Washington for a week trying to head off Trump's Section 338 tariffs — a rarely used trade law that, unlike earlier rounds, doesn't recognize USMCA certificates of origin for the goods it covers. Autos, alcohol, and dairy are all on the list, but autos are the sticking point. Canada is pu...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment